Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

Samah Hayek, Yatir Ben-shlomo, Noa Dagan, Ben Y. Reis, Noam Barda, Eldad Kepten, Alina Roitman, Shachar Shapira, Shlomit Yaron, Ran D. Balicer, Doron Netzer, Alon Peretz

Research output: Contribution to journalArticlepeer-review

Abstract

REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-19-related hospitalization, severe disease, and death. We compared patients infected with Delta variant and treated with REGEN-COV (n = 289) to those infected but not-treated with REGEN-COV (n = 1,296). Demographic and clinical characteristics were used to match patients and for further adjustment as part of the C0x model. Estimated treatment effectiveness was defined as one minus the hazard ratio. Treatment effectiveness of REGEN-COV was 56.4% (95% CI: 23.7–75.1%) in preventing COVID-19 hospitalization, 59.2% (95% CI: 19.9–79.2%) in preventing severe COVID-19, and 93.5% (95% CI: 52.1–99.1%) in preventing COVID-19 death in the 28 days after treatment. In conclusion, REGEN-COV was effective in reducing the risk of severe sequelae in high-risk COVID-19 patients.

Original languageEnglish
Article number4480
JournalNature Communications
Volume13
Issue number1
DOIs
StatePublished - 1 Dec 2022

ASJC Scopus subject areas

  • Chemistry (all)
  • Biochemistry, Genetics and Molecular Biology (all)
  • General
  • Physics and Astronomy (all)

Fingerprint

Dive into the research topics of 'Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes'. Together they form a unique fingerprint.

Cite this